26
Participants
Start Date
November 3, 2019
Primary Completion Date
December 31, 2022
Study Completion Date
February 10, 2023
Ixazomib/Pomalidomide/Dexamethasone
"Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged \<75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
CHU de Caen, Caen
CHU de Dijon, Dijon
Centre Hospitalier de Périgueux, Périgueux
Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse
CHU Bordeaux - Hôpital Haut Leveque, Pessac
CHU Saint Eloi, Montpellier
CHU Pontchaillou, Rennes
Hôpital Privé Sévigné, Cesson-Sévigné
CHRU Bretonneau, Tours
CHU de Grenoble, Grenoble
CHRU Hôtel Dieu, Nantes
CHU Angers, Angers
CHU de Reims Hôpital Robert Debré, Reims
Hôpitaux de Brabois - CHRU de Nancy, Vandœuvre-lès-Nancy
CHRU Hôpital Claude Huriez, Lille
Centre hospitalier de Dunkerque, Dunkirk
Centre hospitalier de la côte basque, Bayonne
Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg
Centre Hospitalier Lyon Sud, Pierre-Bénite
Hôpital Saint Louis, Paris
Centre Henri Becquerel, Rouen
CH Avignon - Centre Hospitalier H.Duffaut, Avignon
Centre hospitalier départemental de Vendée, La Roche-sur-Yon
CHU de Poitiers, Poitiers
CHU de Limoges, Limoges
Hôpital Avicenne, Bobigny
CHU Henri Mondor, Créteil
Hôpital de l'Archet 1, Nice
Collaborators (3)
AXONAL
UNKNOWN
Nantes University Hospital
OTHER
University Hospital, Grenoble
OTHER
Euraxi Pharma
INDUSTRY
QPS Holdings LLC
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Takeda
INDUSTRY
Intergroupe Francophone du Myelome
NETWORK